Celerion (United Kingdom)

Recent papers from Celerion (United Kingdom)

1. First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitorJournal of Allergy and Clinical Immunology · 2026
2. Randomized trial of pharmacokinetic and pharmacodynamic effects of 13.2 mg intranasal epinephrine treatment in congestionAnnals of Allergy Asthma & Immunology · 2024
3. Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction StudiesPharmaceutics · 2024
4. Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT LiabilityClinical Pharmacology & Therapeutics · 2024
5. 2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( PART 2 – Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies)Bioanalysis · 2024
6. nanoCLAMP potently neutralizes SARS-CoV-2 and protects K18-hACE2 mice from infection2023
7. The Impact of N-nitrosamine Impurities on Clinical Drug DevelopmentJournal of Pharmaceutical Sciences · 2023
8. Rifampin Drug–Drug–Interaction Studies: Reflections on the Nitrosamine Impurities IssueClinical Pharmacology & Therapeutics · 2022
9. Regulation of CTLA‐4 recycling by LRBA and Rab11Immunology · 2021
10. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitisRespiratory Research · 2020
11. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPDRespiratory Research · 2019
12. Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese SubjectsNicotine & Tobacco Research · 2018
13. Early drug development: assessment of proarrhythmic risk and cardiovascular safetyExpert Review of Clinical Pharmacology · 2016
14. 8th GCC: Consolidated Feedback to US FDA on The 2013 Draft FDA Guidance on Bioanalytical Method ValidationBioanalysis · 2014
15. Techniques for Hyaluronidase-Facilitated Subcutaneous Fluid Administration With Recombinant Human HyaluronidaseJournal of Infusion Nursing · 2011